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Whey-acidic-protein (WAP) four-disulphide core (WFDC) proteins have important roles in the regulation
of innate immunity, anti-microbial function, and the inhibition of inﬂammatory proteases at mucosal
surfaces. It was recently demonstrated that the WFDC protein, prostate stromal 20 (ps20), encoded by
the WFDC1 gene, is a potent growth inhibitory factor, and shares with other WFDC proteins the ability to
modulate wound healing processes and immune responses to viral infections. However, ps20 remains
relatively uncharacterised at the protein level.
Using a panel of ps20 antibodies for western-blotting (WB), ELISA and immunoafﬁnity puriﬁcation,
we isolated, biochemically characterised and tested ps20 preparations for three biological properties:
(i) interactions with glycosaminoglycans (GAG) (ii) inhibition of cell proliferation, and (iii) transgluta-
minase2 (TG2) mediated crosslinking of ps20 to ﬁbronectin, a process implicated in wound healing. We
show herein that ps20 preparations contain multiple molecular forms including full-length ps20 (re-
solving at E27 kDa), an exon 3 truncated form (E22 kDa) that lacks aa113–140, and variable amounts of
a putatively cleaved lower MW (E15–17 kDa) species. Untagged puriﬁed ps20 preparations containing a
mixture of these forms are biologically active in signiﬁcantly suppressing prostate cell proliferation. We
show that one mechanism by which lower LMW forms of ps20 arise is through cathepsin L (CL) cleavage,
and conﬁrm that CL cleaves ps20 at the C-terminus, but this does not inhibit its growth inhibitory
function. However, CL cleavage abrogated the interaction between ps20 and solid-phase ﬁbronectin.
Therefore, we demonstrate for the ﬁrst time that LMW forms of ps20 that lack a C-terminal im-
munogenic epitope can arise through CL cleavage and this cleavage impairs multimerisation and po-
tential capacity to cross-link to ECM, but not the capacity of ps20 to inhibit cell proliferation. We propose
that ps20 like other WFDC proteins can become associated with GAGs and the ECM. Furthermore, we
suggest post-translational processing and cleavage of ps20 is required to generate functional protein
species, and TG2 mediated crosslinking and CL cleavage form components of a ps20 regulatory appa-
ratus.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).an open access article under the C
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mith),1. Introduction
The WFDC family of proteins are potent modulators of in-
ﬂammation deﬁned by presence of a tightly coiled globular WAP-
four-disulphide-core domain. Members possess pleiotropic roles
in the inhibition of inﬂammatory proteases, abrogation of micro-
bial growth, and the ability to regulate the responses to viral in-
fections [1,2]. ps20 is a WFDC family member for which no pro-
tease inhibitory function has yet been elucidated, but nonetheless
possesses potent immune regulatory functions including the
modulation of cell and molecular responses to viral infection and
wounding [2–4]. Other data show ps20 to be a physiologically
pleiotropic protein able to regulate numerous downstream hostC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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verse as tumourigenesis and HIV infectivity [3,5]. Unique within
the WFDC family, ps20 is a potent inhibitor of cellular proliferation
and has putative role in regulating replicative senescence [6–9]. In
keeping with this notion WFDC1/ps20 is downregulated in diverse
tumour types including prostate cancer [9–12].
WFDC1 is expressed in two isoforms at the mRNA level, one
containing a full length 660 mRNA coding sequence formed of
6 exons, and a truncated form containing a 576 bp coding se-
quence in which exon 3 is absent. Both were originally observed in
prostate cancer cell lines and patient samples [6]. We have re-
cently published evidence that both forms are transcribed and
expressed at the protein level [13]. Despite the importance of
WFDC family proteins in numerous disease processes, their bio-
chemistry is poorly understood, including their means of inter-
acting with cells and signalling. Although all WFDC factors are
secreted, all members including ps20 lack known cell surface re-
ceptors, or the ability to signal by any known mechanism, despite
showing signiﬁcant cell-intrinsic functionality [14]. While binding
to a number of cell surface proteins has been observed for SLPI,
none of these has been linked to speciﬁc cellular functions [2].
Interestingly however, both SLPI and elaﬁn are known to interact
with glycosaminoglycans (GAGs) [15,16]. These sulphated dis-
accharide chains are ubiquitous at the surface of cells and in the
ECM where they sequester soluble proteins and mediate ligand-
receptor interactions [17,18]. It has been proposed that endocytic
and macropinocytotic uptake of proteins may involve proteogly-
cans [19,20], which may be pertinent to WFDC protein function
given that labelled SLPI has been shown to enter cells, locate to the
nucleus, and function by binding to NFκB regulatory elements
[21,22].
In addition to binding GAGs, SLPI and elaﬁn interact with TG2, a
calcium dependent enzyme responsible for crosslinking of protein
multimers [23]. Furthermore, both SLPI and elaﬁn undergo TG2
mediated crosslinking to ECM components ﬁbronectin and elastin
[24,25] tethering them within the ECM from where they can per-
form their protease inhibition and immune-modulatory functions.
WFDC proteins are also susceptible to cleavage by cathepsins;
elaﬁn is cleaved from its precursor trappin-2 by cathepsins-L and
-K [26] while SLPI is inactivated by cleavage by cathepsins-B, L and
S [27]. TG2 crosslinking and cathepsin cleavage are therefore po-
tential mechanisms for regulating WFDC protein function and may
be pertinent to ps20 function.
Few papers have investigated the use of soluble ps20, despite
its therapeutic potential as a potent inhibitor of tumour growth
and immune regulatory factor. Herein we demonstrate a novel
method for the puriﬁcation of ps20, and demonstrate ps20-GAG
interactions. Furthermore we demonstrate that ps20 cleavage by
CL does not abrogate ps20 growth inhibitory function. Lastly, we
show that ps20 interacts with both TG2 and cathepsins, and pro-
pose a role for these processes in regulation of ps20 bioavailability
within the ECM.2. Materials and methods
2.1. Cell lines
PC-3, and WPMY-1 cells were purchased from the ATCC
(Manassas, Virginia). HeLa and 293T cells were a kind gift of Pro-
fessor Mike Malim (KCL, dept. infectious Diseases). 293F cells, a
suspension-culture adapted variant of HEK 293T, were purchased
from Life Technologies. Cell lines were routinely cultured in DMEM
(WPMY-1, 293T) or RPMI (HeLa, PC-3) with 10% FCS, 2mM L-glu-
tamine and antibiotics at 37 °C with 5% CO2 in 75 cm2 ﬂasks. 293F
were cultured in FreeStyle™ 293 expression medium in conicalﬂasks. All media and serum was purchased from Gibco (Life
Technologies).
2.2. Antibodies
Ps20 antibodies: Mouse monoclonal 1G7 was generated as
previously described [6]. C-terminal and N-terminal polyclonal abs
speciﬁc to ps20 were generated by Eurogentech (Southampton,
UK) by inoculation of rabbits with peptides AEEAGAPGGPRQPRA
and KNVAEPGRGQQKHFQ respectively (Supplementary Fig. 1).
Puriﬁcation was by afﬁnity chromatography to the immunising
peptide. Where these antibodies are used in western blotting (WB)
they are labelled C-term and N-term respectively. Antibody to V5-
tag was from Sigma. Antibody to β-actin was from Santa Cruz
Biotechnology. HRP-conjugated goat anti-rabbit and rabbit anti-
goat used for WB were from thermo-scientiﬁc.
2.3. Cloning and veriﬁcation of full-length and truncated ps20
WFDC1 mRNA transcripts were ampliﬁed from HeLa-lysate
with speciﬁc primers: 5′-GGGAGGAAATGCCTTTAACC-3′ and 5′-
TGCTTGCCGTTGCTTTACTG-3′. EcoR1 and Xho1 sites were added
through ampliﬁcation with Taq polymerase (New England Biolabs)
using the primers fwd 5′-ATATATACTCGAGGCATGCCTTTCCGGC-3′
and rev 5′-ATATATGAATTCGCTTACTGAAAGTGCTTCTG-3′ and the
resulting products ligated into the MIGR1-EGFP plasmid (a kind
gift of Professor Mike Malim). Plasmids were veriﬁed by sequen-
cing (MWG euroﬁns).
2.4. Puriﬁcation of ps20 for functional studies
Four sources of ps20 were used as described below. For func-
tional studies, we generated sufﬁcient quantities of both native
ps20 puriﬁed from HeLa cell conditioned media (described in
Section 2.4.1 below) as well as recombinant (r) ps20 (described in
Section 2.4.2 below). For additional biochemical analyses, we
generated recombinant full length (rps20FL), and recombinant
truncated ps20 (rps20TR), representing ps20 molecule expressed
from the full length WFDC1 coding sequence, or an isoform in
which the whole of exon 3 has been removed (described in Section
2.4.3 below). Lastly, in some experiments we used a V5-His tagged
recombinant ps20 (rps20V5) (described in Section 2.4.4 below).
2.4.1. ps20HeLa
Puriﬁcation of native ps20 secreted by HeLa cells was per-
formed by BIOSERV Ltd (Shefﬁeld, UK). Brieﬂy, HeLa cells were
cultured in HyClone™ SFM4CHO™ Media (GE healthcare) in roller
bottles for 72 h. Conditioned media (CM) was concentrated 10
using a vivaﬂow 200, 5 kDa MWCO PES cassette (GE healthcare)
and then puriﬁed by standard chromatography on an anti-ps20
MAB, 1G7 immunoafﬁnity column. CM was clariﬁed/concentrated
and absorbed to an anti-ps20 (1G7) coupled NHS activated se-
pharose column in 25 mM Tris HCl/150 mM NaCl (pH 7.2) at a ﬂow
rate of 1 ml/min. Washing was with 5 column volumes of binding
buffer and elution of ps20 was with 0.2 M glycine buffer (pH 2.3).
Eluate was neutralised immediately with 1 M Tris pH 9 and dia-
lysed overnight against PBS and aliquots stored at 80 °C. ps20
concentration was determined using a ps20 ELISA assay described
in section below.
2.4.2. rps20293F
To generate sufﬁcient recombinant ps20 (rps20) for functional
studies, we used 293 F cells, a suspension adapted cell line derived
from 293T cells. An untagged ps20 construct (pBK-WFDC1) gen-
erated in Dr D Rowley's laboratory (kind gift) by cloning WFDC1
from prostate stromal cells were transfected into 293F cells using
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lume FreeStyle™ 293 expression medium in conical ﬂasks for 72 h.
ps20 was puriﬁed from CM on an 1G7 afﬁnity column, as de-
scribed in Section 2.4.1 above.
2.4.3. rps20FL, rps20TR
In addition, smaller quantities of rps20FL and rps20TR were
generated by cloning WFDC1 from HeLa cells (described in pre-
ceding section) and transfecting these constructs into adherent
293T cells followed by puriﬁcation of the crude CM containing the
soluble protein on 1G7 immunoafﬁnity column exactly as de-
scribed above for rps20293F. These preparations were used for se-
lect biochemical characterisation studies.
2.4.4. rps20V5
Full length WFDC1 isolated from HeLa cells was cloned into a
drosophila expression vector with a V5 and His tag (rps20V5).
Drosophila SH2 cells were used for protein expression and pur-
iﬁcation was by nickel-chelate as previously described [5]. Other
studies (not shown) revealed that a C-terminal tag impacted bio-
logical function; therefore, rps20V5 was used only for biochemical
characterisation.
2.5. MTS viability assay
PC-3, or WPMY-1 cells seeded at 2000/well in 96 wells plates
were cultured in the indicated conditions for 72 h followed by
addition of 15 μl of Celltiters reagent for 1 h. Colourimetric
reading was taken by measuring absorbance at 490 nm using a
plate reader (Biorad).
2.6. ps20 ELISA
96-well plates (NUNC, Thermo Fischer Scientiﬁc, USA) were
coated with anti-ps20 rabbit-polyclonal antibody (5301 or 651) at
8 μg/ml overnight and blocked with 200 μl PBS with 1% Bovine
serum albumin (BSA) (Sigma Aldirch) (w/v) for 2 h at room tem-
perature (RT). 100 μl of samples or CM were incubated for 2 h at
RT. An 8 point standard curve was prepared using serial 2 fold
dilutions of ps20-GST fusion protein in PBS purchased from Pro-
teintech (Manchester, UK) starting at 50ng/ml. Washing was with
PBS with 0.2% Tween20 (v/v). Detection was with 1G7 conjugated
to HRP at 3.7 μg/ml in PBS with 1% BSA (w/v) and 0.4%Tween20
(v/v)(Sigma Aldrich) for 2 h, and developed with 150 μl of sub-
strate buffer (Sigma fast OPD, Sigma Aldrich) and stopped at
30 min by addition of 25 μl 4 M H2SO4. Absorbance at 490 nm was
measured using a colorimetric plate reader (Biorad). The unknown
concentrations of ps20 in samples were determined relative to the
ps20-GST standard by 4 parameter logistic nonlinear regression
using prism 4 (Graphpad).
2.7. SDS-PAGE/western blotting
Samples were prepared in NuPage™ LDS loading buffer and
reducing reagent, boiled for 5 min and electrophoresed on 12%
NuPage Bis-Tris gels (all Invitrogen Life Technologies). Gels were
stained with Lumitein stain (Biotium, CA, USA) or silver stain
(Sigma) according to manufacturer's instructions and visualised
using a typhoon ﬂuorescent scanner (GE Healthcare), or protein
was transferred to nitrocellulose membranes and blocked using
PBS with 5% milk (w/v) and 0.2% Tween20 (v/v). Hybridisation was
overnight at 4 °C with anti-ps20 primary antibodies at 1:500 di-
lution and secondary anti-rabbit at 1:2000 dilution, simulta-
neously. Washing was with 10 ml PBS with 0.2% Tween20 (v/v) at
room temperature 6 times for 10 min followed by incubation with
ECL substrate (Thermo scientiﬁc) and acquisition using theImagequant™ system (GE Healthcare).
2.8. Glycosaminoglycan binding studies
Using an Aktӓ-puriﬁer FPLC system (GE Healthcare). 5 ml of
293T-ps20 CM was absorbed to a 1 ml HiTrap™ heparin-coated
column (GE Healthcare) followed by 5 CV of washing with 50 mM
Tris–HCl buffer (pH 7.5). A 0–0.5 M NaCl gradient was then applied
to the column over 10 CV while 0.5 ml fractions were collected.
These were then subjected to WB with 1G7. Heparin binding
plates (BD Biosciences) coated overnight with 25 μg/ml GAGs;
heparin sulphate, chondroitin sulphate A, and chondroitin sul-
phate C (all Sigma Aldrich) and blocked in PBS with 1% BSA (w/v).
rps20293F diluted in PBS was absorbed for 2 h prior to washing and
detection with 1G7-HRP. 100 μl of tetramethylbenzidine ELISA
substrate was added and absorbance at 450 nm was measured as
described for the ps20 ELISA above. A baseline was established by
binding of rps20293F to a BSA solid phase. For the cell binding assay
293T cells, pre-treated with sodium chlorate where indicated,
were resuspended using PBS (Gibco) with 4 mM EDTA (Sigma
Aldrich). 106 cells were incubated with rps20V5þ/ heparin with
agitation for 1 h. Cells were washed once with 1 ml PBS and re-
suspended in 50 μl tissue lysis buffer (Sigma). Samples were then
subjected to WB as indicated.
2.9. Transglutaminase studies
Tissue transglutaminase (TG2) from guinea pig liver (Sigma
Aldrich), was added at a ﬁnal concentration of 0.1 U/ml to samples
containing ps20 with 4 mM DTT and 10 mM CaCl2 and incubated
between 5 min and 3 h at 37⁰C. Transglutamination was stopped
by adding WB loading buffer and samples were boiled and ana-
lysed by WB. A modiﬁed ELISA used nunc 96 well plates coated
overnight with ﬁbronectin (Sigma) at 1 μg/ml in PBS with 1% BSA
(w/v). 80 μl of TG2 (0.1 U/ml) in 50 mM TRIS buffer with 10 mM
CaCl2 and 4 mM DTT (pH 7.5) were added to wells and 20 μl of
ps20 was added for 2 h at 37 °C. Detection was with 1G7 con-
jugated to HRP at 3.7 μg/ml in PBS with 1% BSA (w/v) and 0.4%
Tween20 (v/v)(Sigma Aldrich) for 2 h, and developed with 150 μl
of substrate buffer (Sigma fast OPD, Sigma Aldrich) and stopped at
30 min by addition of 25 μl 4 M H2SO4. Absorbance at 490 nm was
measured using a colorimetric plate reader (Biorad).
2.10. Cathepsin cleavage studies
Cathepsin L (CL) or cathepsin B (R&D systems) were incubated
with a molar excess of ps20 in 50 mM MES buffer with 4 mM DTT
(pH 5.5) for 1 h at 37 °C þ/ inhibitors E-64c or E-64d (Sigma).
Reactions were stopped by addition of WB loading buffer and
samples were analysed as described. For the modiﬁed ELISA assay;
following ps20 crosslinking to ﬁbronectin by TG as described
above, CL was prepared in 50 mM MES with 4 mM DTT (pH 5.5)
and added to ELISA plates for 2 h at 37 °C. Washing and detection
were as described above.
2.11. Statistical tests
Tumour cell proliferation was evaluated with an unpaired t test.
Statistical analysis was performed with Prism version 4 (GraphPad
Software, San Diego, CA). Error bars represent SE, and Po0.05 was
considered statistically signiﬁcant.
3. Results
3.1. ps20 enrichment through interaction with glycosaminoglycans
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Fig. 1. ps20 enrichment through interaction with GAGs reveals multiple molecular species. (A) 5 ml of rps20-transfected 293T CM was absorbed to a heparin-sepharose
column and eluted with 0–0.5 M NaCl gradient. Fractions were subjected to WB with ab1G7 under reducing conditions. (B) 5 ml of rps20-transfected 293T CM or 1 ml of a
50 ng/ml solution of rps20V5 was absorbed to a heparin-sepharose column and eluted with 0–0.5 M NaCl gradient. Individual fractions were assayed for ps20 by ELISA. (C)
rps20293F at the indicated concentration was bound to GAG (or BSA) coated wells for 2 h and detected using anti-V5-HRP. Baseline binding to BSA for each concentration of
rps20293F was subtract. Charts show speciﬁc ODs; mean and SEM of two experiments in duplicate. (D–E) ps20v5 μg/ml was absorbed to 293T cells (106 in presence or absence
of heparin (D) or to cells treated with sodium chlorate (E). Cell were washed, lysed and subjected to WB under reducing conditions.
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We predicted that ps20 would bind GAGs based on known
interactions of family members [27] and explored using this in-
teraction to initially isolate and characterise the protein. To in-
vestigate the interaction between ps20 and GAGs we initially used
crude conditioned media (CM) from 293T cells transfected to ex-
press ps20. CM was directly absorbed to and eluted from a he-
parin-sepharose column using a NaCl gradient (Fig. 1(A)). Notably,
the concentrated 0.5 ml fractions eluted by addition of increasing
concentrations of NaCl revealed for the ﬁrst time numerous ps20
protein species of different molecular weights (MW) ranging from
27 kDa to 15 kDa. Fig. 1(B) shows the elution proﬁle of ps20 using
an ELISA to detect ps20 in the eluted fractions. The majority of
bound ps20 was clearly eluted between 0.25 and 0.35 M NaCl. We
then investigated the interaction between ps20 and physiologi-
cally relevant GAGs. Unlike heparin, heparan-sulphate and chon-
droitin-sulphate are expressed on the surface of cells and in the
extracellular matrix (ECM) and have been shown to have im-
portant functions in the regulation of surface signalling and pro-
tein trafﬁcking. Interestingly, rps20293F had notably higher afﬁnity
for heparin-sulphate than chondroitin-sulphate-A, while no spe-
ciﬁc binding to chondroitin-sulphate-C was observed at the con-
centrations tested. Next, to explore if ps20 can interact with cell
associated GAGs we used a puriﬁed C-terminal tagged re-
combinant ps20 (rps20V5) probed with an antibody to the V5 tag.Notably, this tagged rps20V5 had a similar elution proﬁle to un-
tagged ps20 when absorbed and eluted using heparin-sepharose
(Fig. 1(B)). 293T cells were treated with rps20V5 in the presence of
absence of soluble heparin. Western blot analysis with anti-V5 Ab
conﬁrmed cellular rps20V5 retention, which was interrupted in a
concentration dependent manner by heparin (Fig. 1(D)). Further-
more, treatment of cells with sodium chlorate to abrogate surface
glycosylation prior to treatment with rps20V5 reduced this inter-
action (Fig. 1(E)). Together these data show that ps20 interacts
with heparin and physiologically relevant GAGs, and can bind to
cells through interactions with GAGs.
3.2. Immunoafﬁnity puriﬁcation enables isolation of full length and
low molecular weight forms of ps20 with growth inhibitory biological
activity
To conﬁrm the presence of multiple ps20 molecular forms, we
used standard anti-ps20 Ab immunoafﬁnity column chromato-
graphy to generate ps20 fractions suitable for downstream biolo-
gical and biochemical analysis. CM of 293F cells transfected to
express pBK-WFDC1 plasmid DNA (Fig. 2(A)) was puriﬁed on anti-
ps20, 1G7 MAb column. This ps20 preparation was named
rps20293F. Mass spec analysis revealed one signiﬁcant contaminant
in this material which was galectin-3 binding protein (G3BP).
Western blotting with afﬁnity puriﬁed anti-ps20 antibodies re-
vealed one predominant molecular species of ps20 at E27 kDa,
Fig. 2. Puriﬁcation of functionally active ps20 using anti-ps20 immunafﬁnity. (A–B) Puriﬁed rps20293F was subjected to SDS-PAGE followed by silver staining (A) or WB with
antibodies to C- or N-terminal epitopes (B). (C) ps20HeLa is shown alongside CM from 293T cells expressing pBK-WFDC1 plasmid as a positive control. The CM contained 10%
FCS and there is a large amount of non-speciﬁc immunoreactivity to serum components at 60–70 kDa. Samples were electrophoresed under reducing (R) or non-reducing
(NR) conditions to distinguish monomeric from multimeric protein structures. Arrowheads indicate the ps20 FL species, arrows the ps20 TR species, and LMW species are
indicated with asterisks. (D) PC-3, or WPMY-1 cells were treated with rps20293F (8.3 nM) and growth assessed by MTS at 72 h. (E) PC-3, or WPMY-1 cells were treated with
68pM ps20HeLa (68 pM) and growth assessed by MTS at 72 h. (D and E) Mean and SEM of 3 experiments performed in duplicate. *Po0.05, **Po0.001 by students T test.
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22 kDa and 15 kDa (Fig. 2(B)). The concentration of rps20293F is
shown in Table 1. Next, to investigate if multiple molecular formsof ps20 are natively expressed, 1G7 immunoafﬁnity column was
again used to purify ps20 from a suspension culture of human
HeLa cells (henceforth ps20HeLa), which we have previously
Table 1
Immunafﬁnity puriﬁed batches of ps20 used in this study.
ps20 batch Concentration Molar concentration
(from ps20 ELISA) (based on MW of 24 kDa) (nM)
rps20293F 2 μg/ml 83
ps20HeLa 15 ng/ml 0.68
rps20FL 190 ng/ml 7.9
rps20TR 184 ng/ml 7.64
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[5].
Both the 293F- and HeLa-derived ps20 preparations rps20293F
and ps20HeLa respectively) were characterised using anti-ps20
antibodies speciﬁc to N- and C-terminal regions. These experi-
ments revealed that the 27 kDa protein in both preparations was
recognised by both the C- and N-terminal antibodies (Fig. 2(B) and
(C) arrowheads). The second 22 kDA protein was also recognised
by both these antibodies and based on MW is likely the truncated
form of ps20 encoded by an mRNA lacking exon 3, as previously
reported (Fig. 2(B) and (C) arrows, and Supplementary Fig. 1) [13].
The third minor band at E15 kDa, is only detected by the
C-terminal antibody in both rps20293F and ps20HeLa preparations
(Fig. 2(B) and (C) asterisks), suggesting that this is a product of
proteolytic cleavage close to the N-terminus of the molecule.
Previous studies have shown ps20 to display growth inhibitory
effects on prostate stromal cells (6). Therefore immunoafﬁnity
puriﬁed rps20293F and the ps20HeLa were added to PC-3 and
WPMY-1 cells at a concentration comparable with that observed in
previous studies [28]. The rps20293F preparation inhibited both PC-
3 and WPMY-1 by 50% and 30% respectively (Fig. 2(D)). Likewise,
ps20HeLa also induced potent growth inhibition on these cells
(Fig. 2(E)), however, notably ps20HeLa was effective at a con-
centration 2 logs below those observed with rps20293F (Fig. 2(D)
and (E) and Table 1) or reported previously [28]. These experi-
ments suggest that i) ps20 is cleaved into LMW species that lack
the N-terminus, and that ii) ps20 preparations that contain these
forms are functionally active.
3.3. Cathepsin L cleaves ps20 at C-terminus with no impact on ps20
growth inhibitory function
We predicted that the lower MW minor forms of ps20 present
in rps20293F and ps20HeLa (Fig. 2(B) and (C)) preparations may arise
by proteolytic cleavage by cathepsins or other extracellular pro-
teases, based on similar characteristics of other WAP proteins
[26,29]. This was formally tested ﬁrst using sequence veriﬁed
rps20 preparations that lacked the minor lower MW forms:
namely, rps20FL, and the exon 3 truncated rps20TR (generated as
described in materials and methods, the concentrations of ps20
preparations are shown in Table 1). These samples each resolved
as a single ps20 band at the expected size of 27 kDa and 22 kDa
respectively (Fig. 3(A) and (B) right panel).. These puriﬁed rps20FL
and rps20TR preparations were then subjected to proteolytic
cleavage. Numerous proteases tested including furin, thrombin,
various matrix metalloproteases (not shown) and cathepsin-B (CB)
(Fig. 3(A)) failed to cleave ps20. However, when incubated with
cathepsin-L (CL) a 4–6 kDa cleavage of both rps20FL and rps20TR
was clearly evident when probed with the N-terminal speciﬁc
anti-ps20 antibody (Fig. 3(B), upper panels). In contrast, when
probed with the C-terminal anti-ps20 antibody (Fig. 3(B), lower
panels), we observed the disappearance of ps20, highlighting a
speciﬁc CL cleavage near the C-terminus.
Addition of CL inhibitors (E64c and E64d) to a CL-rps20FL
cleavage reaction inhibited this process highlighting the speciﬁcity
of CL cleavage (Fig. 3(C)). On the other hand heparin did notenhance or inhibit this cleavage, further highlighting CL cleavage
speciﬁcity (Fig. 3(C)). To determine if ps20 cleavage by CL im-
pacted biologically activity, we added CL to rps20293F (Fig. 3(D) and
(E) lower panel). This revealed a clear shift of electrophoretic
mobility of ps20 bands (Fig. 3(D), arrows), resulting in a number of
further LMW ps20 species (E10 kDa, 15 kDa), suggesting CL was
able to cleave ps20 species with an intact C-terminus. To test
impact on biological activity, CL cleaved rps20293F was added to
WPMY-1 prostate cells. CL cleavage resulted in no change to
rps20293F growth inhibitory function (Fig. 3(E)).
Taken together, these experiments indicate that CL cleaves ps20
at the C terminus to generate minor lower MW ps20 species, and
does not abrogate ps20 growth inhibitory function.
3.4. CL mediated cleavage is important for ps20 cross-linking to ﬁ-
bronectin by transglutaminase
As CL cleavage did not abrogate the growth inhibitory activity
of ps20, we tested its importance in a second function that WAP
proteins are implicated in: that is cross-linking to the ECM via
transglutaminase (TG2) [24,25]. The interaction between ps20 and
solid phase TG2 was ﬁrst tested using rps20V5 in a modiﬁed ELISA,
which conﬁrmed a high-level of binding of ps20 to TG2 relative to
a BSA solid phase (not shown).
We then assessed the ability of TG2 to catalyse the formation of
ps20 into high MW (HMW) forms using rps20293F. Fig. 4(A), right
panel, shows a TG2 dependent multimerisation of rps20293F to a
predominant E150 kDa species, and a less distinct HMW species,
which failed to migrate into the gel, suggesting that TG2 induces
the formation of higher order multimers of E150 kDa and above.
Interestingly, the same experiment WB using a ps20 C-terminal
antibody (Fig. 4(A), left panel) shows only the monomeric protein,
which is absent following incubation with TG, but fails to reveal
the multimerised forms, implying the involvement of the
C-terminal glutamine residues in the transglutaminase reaction,
which would block binding of our C-terminal antibody. To further
verify that this ﬁnding was the result of a TG2 mediated transa-
midation reaction we incubated rps20V5, which can be visualised
by probing the c-terminal V5 tag, with TG2 for the indicated time,
or in the presence of EDTA, or competitive TG2 inhibitor cystamine
(Fig. 4(B)). TG2 catalysed the formation of a multimeric E150 kDa
ps20 species, and a continuum of higher order ps20 species
4150 kDa. Conversely, the presence of chelating agent EDTA, or
cystamine prevented the formation of any such multimerisation,
providing a strong indication that TG2 induced transamidation
was the cause of ps20 multimerization.
We then investigated the interaction between ps20 and ﬁ-
bronectin, a component of the ECM with which SLPI and elaﬁn
have also been shown to functionally interact and become cross-
linked to [24,25]. TG2 efﬁciently catalysed cross-linking of
rps20293F to ﬁbronectin in a modiﬁed ELISA assay; only a small
level of binding to ﬁbronectin was observed in the absence of TG2,
or the presence of EDTA, suggesting that bona ﬁde TG2 dependent
cross-linking of ps20-ﬁbronectin was occurring (Fig. 4(B)). In
contrast, no signiﬁcant interaction was seen between ps20 and
BSA either in the presence or absence of TG2, suggesting the
crosslinking between ﬁbronectin and ps20 catalysed by TG2 was a
speciﬁc interaction. In order to assess whether the CL cleavage
impacted this function, we performed a digestion of rps20293F
with CL, followed by incubation with TG2 to mediate the forma-
tion of HMW multimers (Fig. 4(C)). Multimerisation is far less
apparent in rps20293F which has been cleaved by CL, again sug-
gesting that TG2 mediated cross-linking involves the C-terminus
of ps20 which has 3 glutamine residues within the last 10 aa,
which is the predicted cleavage site of CL. We then tested if ps20
immobilised and bound to ﬁbronectin could be cleaved by CL
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N-terminal portion of the molecule in solution (Fig. 4(D)). As be-
fore, we observed high levels of ps20 cross-linked to ﬁbronectin in
the presence of TG2, but far lower with either solid phase BSA or
where TG2 was absent (Fig. 4(D)). Following the crosslinking step,
the plate was washed and incubated with CL, which reduced the
ps20 bound to ﬁbronectin almost to baseline levels. This demon-
strates that even after ps20 is cross-linked to ﬁbronectin via TG2, it
is susceptible to CL-mediated cleavage at the C-terminus.
Taken together these data show that ps20 interacts with TG2
and undergoes multimerisation and cross-linking to the ECM
protein ﬁbronectin. Furthermore, once cross-linked to ﬁbronectin,
CL can continue to cleave ps20 at the C-terminus.4. Discussion
Despite evidence of signiﬁcant functional relevance to cancer,
cell senescence, and the outcome of viral infections, ps20 remains
largely uncharacterised at the protein level. We demonstrate that
ps20 is a GAG binding factor like SLPI and elaﬁn [15,16], capable of
interactions with heparin and physiological GAGs heparan-sulfate
and chondroitin sulphate. Furthermore, ps20-interactions binding
to cells was outcompeted by heparin, suggesting an interaction
with cell surface glycosaminoglycans. Given the current lack of
understanding about the mechanisms of ps20 and other WFDC
protein function, this attribute may have important functional
implications. Notably, SLPI function is mediated by the ability to
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from studies with cationic peptides such as HIV-TAT indicates that
surface-proteoglycans can mediate macropinocytotic protein/
peptide uptake [30,31]. Future work with ps20 and other WFDC
family proteins should therefore consider protein-GAG interac-
tions as a potential mechanism of cellular signalling.
To date, functional investigation of ps20 has been limited by
the available sources of the protein. C-terminal GST tagged protein
is available commercially, although this tag has previously been
shown to interfere with the growth suppression activity [6]. In
addition, we have failed to observe any function in V5-His tagged
ps20, suggesting that C-terminal tags may be broadly inhibitory to
ps20 function. Furthermore, crude CM from cells transfected to
express rps20 has repeatedly failed to inhibit cellular proliferation,
despite achieving high concentrations [13]. We utilised im-
munoafﬁnity chromatography with anti-ps20 1G7 to purify re-
combinant ps20 from 293F cells (rps20293F, Fig. 2(A)) as well as
native ps20 secreted by HeLa cells (ps20HeLa, Fig. 2(C)). In line with
previously published reports [6,28] rps20293F, which contained
multiple LMW forms (E22 kDa, E15 kDa), inhibited growth ofprostate cancer cells (Fig. 2(C)) at low nanomolar concentration,
while the sole contaminant G3BP showed no growth inhibitory
function at micromolar concentrations (not shown). Puriﬁcation of
native ps20 from HeLa CM also revealed multiple LMW anti-ps20
immuno-reactive protein species resolving at E22 kDa and
E15 kDa, and was similarly biologically active in cell growth in-
hibition assays (Fig. 2(E)). Notably, WB of ps20 preparations in-
cluding rps20293F and ps20HeLa with anti-ps20 Ab to both C-and
N-terminal regions revealed the presence of the protein product of
an exon 3 truncated WFDC1 mRNA described [6] and previously
cloned and expressed by our lab [13].
The presence of a prominent cleaved subspecies resolving at
E15 kDa in the ps20HeLa lacking the ps20 N-terminal epitope,
combined with its potent growth inhibitory activity at con-
centrations 2 logs below rps20293F led us to postulate that LMW
ps20 species may be functionally important. To test this possibility
we subjected ps20 preparations to protease cleavage. While
thrombin, furin, metalloproteinase-3 and cathepsin-B failed to
cleave ps20, we showed that CL can efﬁciently cleave all ps20
preparations tested at the C-terminus at concentrations far below
O.J. Hickman et al. / Biochemistry and Biophysics Reports 7 (2016) 328–337336that reported for CL physiological activity [32] (Fig. 3(B)). However,
this resulted in neither enhancement, nor abrogation of rps20293F
mediated growth inhibition (Fig. 3(E)) suggesting CL cleavage is
not a regulator of ps20's growth inhibitory activity. Furthermore,
the use of speciﬁc CL inhibitors, and the fact that cathepsin B and
other proteases had no effect of ps20 suggests that he CL cleavage
reaction is speciﬁc and may have relevance aside from the gen-
eration of growth inhibitory ps20 cleavage products.
To further investigate the putative biological signiﬁcance of CL-
mediated cleavage of ps20, we explored its impact on a second
known function of WAP proteins, that of binding / cross-linking to
the ECM. First we tested if ps20 interacts with transglutaminase2
(TG2). We observed high-afﬁnity binding of ps20 to a TG2 solid-
phase (not shown). TG2 is best known for its ability to cross-link
proteins via a transamination reaction. In line with this we ob-
served the TG2 dependent formation of 150 kDa and higher ps20
multimers (Fig. 4) indicating that TG2 regulates the multi-
merisation of ps20 into non-labile multimers resistant to reduc-
tion by boiling in DTT. Interestingly, untagged ps20 multimers
were only detected by anti-ps20 directed against the N-terminus
of the protein, suggesting ps20 cross-linking involves one or more
of the three glutamines in the immediate C-terminal region of
ps20. Next, and in line with similar studies demonstrating that
SLPI and elaﬁn can cross-link with ﬁbronectin [24,25], we show
here that ps20 can also become cross-linked to ﬁbronectin in a
TG2 dependent fashion. Given the suspected involvement of the
C-terminus in ps20 cross-linking, we then tested the impact of CL
cleavage of ps20 following TG2-mediated ps20 cross-linking to
ﬁbronectin (Fig. 4(D)). Following TG2 mediated cross-linking of
ps20 to ﬁbronectin, the failure to detect ps20 in those conditions
subjected to subsequent CL cleavage (Fig. 4(D)) suggests a possible
mechanism for the release of soluble ps20 from the ECM matrix
through C-terminal cleavage. It remains possible, however, that
the failure to detect ps20 cross-linked to ﬁbronectin, following
cleavage by CL may instead be due to changes to ﬁbronectin solid
phase induced by CL. However, the ultimate effect of liberating
ps20 from the interaction appears to be the same. Lastly, while it is
clear then that CL can cleave ps20 at the C-terminus, and this may
play a role in regulating interactions with ECM components, it is
possible that CL cleavage of ps20 may also have as yet unidentiﬁed
functions. In light of the numerous indications that ps20 possesses
pleiotropic functionality [3–5,9,13,33], it may be the case that CL
and possibly other proteases regulate the function of ps20 through
tissue and cell-type speciﬁc cleavage events by i) generating
functional protein fragments, or ii) abrogating interactions with
other tissue components, such as ﬁbronectin.
Our demonstration that ps20 interacts with GAGs may be
pertinent in light of recent data suggesting TG2 function is regu-
lated at the cell surface through interactions with GAGs. While we
saw no enhanced TG2-dependent multimerization of ps20 in the
presence of soluble heparin (not shown), it may be the case that
within tissues - at the ECM or cell surface - the interaction of ps20,
TG2 [34,35], and CL [36] with surface GAGs regulates the processes
observed herein. We propose that ps20 is secreted by cells in both
FL and TR forms and cleaved into smaller variants by as yet uni-
dentiﬁed proteases. Interactions with GAGs, TG2 and cathepsins
then comprise an apparatus, common to SLPI, elaﬁn and ps20,
whereby bioavailability of ps20 is regulated through the formation
of HMW multimers, or through cross-linking to the ECM, and in-
turn liberated by CL or similar proteolytic cleavage. Using in vitro
assays, we have demonstrated that ps20 has numerous biochem-
ical properties in common with other WFDC family proteins that
will be important to consider in further investigating the function
of this molecule.
It is noteworthy, that despite dozens of publications describing
diverse functional activities of WFDC family proteins, no receptorshave been identiﬁed for any family member. We suggest that due
to the possibly unique properties of this protein family, the stan-
dard secreted-protein interaction with cognate-receptor paradigm
of signalling may not be relevant. For WFDC family proteins there
is increasing evidence that extracellular processing events are
necessary to generate protein fragments which may have diverse
signalling modalities. Some of these functions may involve cognate
receptors, though none have yet been identiﬁed, or they may in-
volve crossing the cell-membrane and interacting with cellular
components, or DNA directly, as has been observed for SLPI [21].
WFDC proteins, including ps20, should therefore be studied fur-
ther to elucidate their biochemical complexity, as they may func-
tion through interesting and as yet unidentiﬁed mechanisms,
broadly relevant to our understanding of cell biology.Acknowledgement
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